{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:03Z","timestamp":1761901683612,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.msard.2020.102700","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T01:29:38Z","timestamp":1608168578000},"page":"102700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk factors for infusion-related reactions following Ocrelizumab infusion in a community setting: Development of an electronic medical record-based explanatory model"],"prefix":"10.1016","volume":"48","author":[{"given":"Hollis","family":"O'Nell-Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia E.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay O.","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-3596","authenticated-orcid":false,"given":"Elizabeth S.","family":"Gromisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2020.102700_bib0001","first-page":"24","article-title":"Movement disorders in early MS and related diseases: A prospective observational study","volume":"9","author":"Abboud","year":"2019","journal-title":"Neurology: Clinical Practice"},{"key":"10.1016\/j.msard.2020.102700_bib0002","series-title":"1988\u20132011: A population-based observational study","first-page":"1819","article-title":"Racial\/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California","volume":"62","author":"Abrah\u00e3o","year":"2015"},{"issue":"1","key":"10.1016\/j.msard.2020.102700_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1756285616666741","article-title":"Targeting B cells in relapsing\u2013remitting multiple sclerosis: from pathophysiology to optimal clinical management","volume":"10","author":"Bittner","year":"2017","journal-title":"Therapeutic advances in neurological disorders"},{"issue":"9648","key":"10.1016\/j.msard.2020.102700_bib0004","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102700_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.msard.2018.11.027","article-title":"Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol","volume":"27","author":"Conte","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.msard.2020.102700_bib0006","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jneumeth.2018.06.016","article-title":"Quantification characteristics of digital spiral analysis for understanding the relationship among tremor and clinical measures in persons with multiple sclerosis","volume":"307","author":"DelMastro","year":"2018","journal-title":"Journal of neuroscience methods"},{"key":"10.1016\/j.msard.2020.102700_bib0007","doi-asserted-by":"crossref","first-page":"S13213","DOI":"10.4137\/PMC.S13213","article-title":"Multiple sclerosis: overview of disease-modifying agents","volume":"6","author":"Finkelsztejn","year":"2014","journal-title":"Perspectives in medicinal chemistry"},{"key":"10.1016\/j.msard.2020.102700_bib0008","unstructured":"Genentech Inc., 2020. Ocrevus Full Prescribing Information. San Francisco, CA."},{"issue":"12","key":"10.1016\/j.msard.2020.102700_bib0009","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1172\/JCI0214873","article-title":"Estrogen alters thresholds for B cell apoptosis and activation","volume":"109","author":"Grimaldi","year":"2002","journal-title":"The Journal of clinical investigation"},{"issue":"3","key":"10.1016\/j.msard.2020.102700_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.msard.2020.102700_bib0011","series-title":"1975-2011. Previous Version. SEER Cancer Statistics Review","article-title":"Cancer Statistics Review","author":"Howlader","year":"2017"},{"issue":"4","key":"10.1016\/j.msard.2020.102700_bib0012","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10552-015-0550-3","article-title":"Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children","volume":"26","author":"Hsu","year":"2015","journal-title":"Cancer Causes & Control"},{"issue":"8","key":"10.1016\/j.msard.2020.102700_bib0013","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.4049\/jimmunol.152.8.3760","article-title":"Adhesion through the LFA-1 (CD11a\/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells","volume":"152","author":"Koopman","year":"1994","journal-title":"The Journal of Immunology"},{"issue":"11","key":"10.1016\/j.msard.2020.102700_bib0014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.clml.2019.08.001","article-title":"Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center","volume":"19","author":"Kowalski","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"11","key":"10.1016\/j.msard.2020.102700_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102700_bib0016","first-page":"853","article-title":"Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell","volume":"89","author":"Matsuzaki","year":"1997","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"10","key":"10.1016\/j.msard.2020.102700_bib0017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"Miller","year":"2007","journal-title":"The Lancet Neurology"},{"issue":"8","key":"10.1016\/j.msard.2020.102700_bib0018","doi-asserted-by":"crossref","first-page":"e69570","DOI":"10.1371\/journal.pone.0069570","article-title":"Headaches in multiple sclerosis patients might imply an inflammatorial process","volume":"8","author":"M\u00f6hrke","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2020.102700_bib0019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.msard.2020.102700_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Therapeutic advances in neurological disorders"},{"issue":"1","key":"10.1016\/j.msard.2020.102700_bib0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1471-2407-11-355","article-title":"Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology","volume":"11","author":"P\u00e9rez-Saldivar","year":"2011","journal-title":"BMC cancer"},{"issue":"9","key":"10.1016\/j.msard.2020.102700_bib0022","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.pmrj.2014.08.941","article-title":"Explanatory versus predictive modeling","volume":"6","author":"Sainani","year":"2014","journal-title":"PM&R"},{"year":"2020","series-title":"Part 1: Mapping multiple sclerosis around the world, key epidemiology findings","key":"10.1016\/j.msard.2020.102700_bib0023"},{"issue":"2","key":"10.1016\/j.msard.2020.102700_bib0024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nic.2016.12.001","article-title":"Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects","volume":"27","author":"Vidal-Jordana","year":"2017","journal-title":"Neuroimaging Clinics"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:48Z","timestamp":1761900708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820307744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":24,"alternative-id":["S2211034820307744"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102700","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for infusion-related reactions following Ocrelizumab infusion in a community setting: Development of an electronic medical record-based explanatory model","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102700"}}